Here is a brief preview of this blast: EMA has issued a warning that Invokana is associated with increased cases of lower limb amputations, particularly toes, in the CANVAS and CANVAS-R studies. The underlying cause remains unknown. While EMA has concluded the risk exists, the issue remains under investigation with FDA.
About The Author
Matthew Maryniak
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.